Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Aptorum Group Limited APM NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • GB • USD

SharesGrow Score
39/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Aptorum Group Limited (APM) is a Biotechnology company in the Healthcare sector, currently trading at $0.95. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: APM trades at a trailing Price-to-Earnings (P/E) of -4.4 (S&P 500 average ~25).

Net income is $1M (loss), growing at +29.4%/yr. Net profit margin is 0% (thin). Gross margin is 2.4% (-3.8 pp trend).

Balance sheet: total debt is $4M against $23M equity (Debt-to-Equity (D/E) ratio 0.15, conservative). Current ratio is 0.78 (tight liquidity). Debt-to-assets is 18.8%. Total assets: $19M.

Analyst outlook: 2 / 2 analysts rate APM as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 6/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

APM SharesGrow Score Overview

49/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 6/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — APM

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
APM: -83.4%/yr revenue is, +29.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet APM: Debt-to-Equity (D/E) ratio 0.15 (conservative), Current ratio is 0.78 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
6/100
APM: Gross margin is 2.4% (-3.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 6/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 2 / 2 analysts rate APM as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.65-4.47
Volume34.37K
Avg Volume (30D)61.75K
Market Cap$6.03M
Beta (1Y)-0.01
Share Statistics
EPS (TTM)-0.19
Shares Outstanding$7.35M
IPO Date2018-12-18
Employees1
CEOChung Yuen Huen
Financial Highlights & Ratios
EBITDA$-1.82M
Net Income$-1.36M
Operating Income$-1.82M
Total Cash$3.45M
Total Debt$3.52M
Net Debt$69.22K
Total Assets$18.69M
Price / Earnings (P/E)-5
Analyst Forecast
Rating ConsensusBuy
Analysts Covering2
Buy 100% Hold 0% Sell 0%
Company Info
CountryGB
ExchangeNASDAQ Global Market
CurrencyUSD
ISINKYG6096M1226

Price Chart

Track all markets on TradingView
APM
Aptorum Group Limited ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.65 52WK RANGE 4.47

People Also View

ARMP
ARMP
Armata Pharmaceuticals, Inc.
$12.06
-6.37%
 SRZN
SRZN
Surrozen, Inc.
$32.02
+0.53%
 IPHA
IPHA
Innate Pharma S.A.
$1.69
+3.68%
 UNCY
UNCY
Unicycive Therapeutics, Inc.
$6.97
+0.43%
 ERYP
ERYP
ERYTECH Pharma S.A.
$0.78
+1.30%
 DYAI
DYAI
Dyadic International, Inc.
$0.88
+0.61%
 NRBO
NRBO
NeuroBo Pharmaceuticals, Inc.
$2.36
+0.00%
 CYAD
CYAD
Celyad Oncology SA
$0.47
-12.96%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message